Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress

Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the best mid-cap stocks with huge upside potential. Oppenheimer reaffirmed its Outperform rating and $75 price target for Revolution Medicines, Inc. (NASDAQ:RVMD) on August 25 after speaking with company management during a West Coast Biotech Bus Tour. The firm highlighted that Revolution recently stated that the initial results from the daraxonrasib RASolute-302 study would be available in 2026, with enrollment continuing smoothly.

As previously disclosed, Revolution Medicines, Inc. (NASDAQ:RVMD) indicated that additional Phase 3 trials of daraxonrasib in adjuvant and first-line pancreatic ductal adenocarcinoma (PDAC) remain scheduled to start this year.

Oppenheimer emphasized that although the filing of daraxonrasib in second-line PDAC may take place in 2026, Revolution Medicines, Inc. (NASDAQ:RVMD) continues to make strides in all areas of its business, and its improved cash sheet is enabling both possible commercialization and continued clinical development.

Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage biotech company that develops cancer medications that target RAS, a major category of genetic abnormalities that are frequently present in difficult-to-treat cancers.

While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.